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1. Introduction 
Glycolysis is an anabolic pathway common in both aerobic and anaerobic organisms. Sugars 
and polysaccharides have to be transformed into glucose or one of its phosphorylated 
derivatives before being processed any further. In the course of degradation, ATP is 
produced. Pyruvate may be regarded as the preliminary final product of the degradation - 
in a strictly formal sense - because it is here that the pathway ramifies: pyruvate is hydrated 
under anaerobic conditions resulting in either lactate (in lactic-acid bacteria) or ethanol (in 
yeast). If glycolysis results in these final products, it is spoken of fermentation. In the 
presence of oxygen pyruvate is converted to acetyl-coenzyme A and oxidized to CO2 in the 
tricarboxylic acid (TCA) cycle (Figure 1). In yeasts, as well in most non-photosynthetic cells, 
mitochondrial oxidative phosphorylation is the main process of ATP synthesis in aerobic 
conditions. Aerobic pathways permit the production of 30 to 38 molecules of ATP per one 
molecule of glucose. Although two molecules of ATP come from glycolysis and two more 
directly out of the TCA cycle, most of the ATP arises from oxidative phosphorylation. 
The main catalytic function of the TCA cycle is to provide reducing equivalents to the 
respiratory chain through the oxidative decarboxylation of acetyl–CoA (8), but every TCA 
cycle intermediate is commonly used by other metabolic reactions. The eight enzymes from 
the TCA cycle are encoded by 15 nuclear genes in S. cerevisiae [1]. The first reaction of TCA is 
catalyzed by citrate synthase (1) and it is the condensation of acetyl–CoA and oxaloacetate 
resulting in the formation of citrate. The second reaction of the TCA is catalyzed by 
aconitase (2), leading to the conversion of citrate into isocitrate. Aconitase is located both in 
mitochondria and in cytosol. The next step of the TCA is the oxidative decarboxylation  
of isocitrate to -ketoglutarate (3). There are three known isoenzymes of isocitrate  
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Figure 1. TCA cycle. 
dehydrogenase, a mitochondrial NAD+-specific one and two NADP+-dependent ones (one 
mitochondrial and the other cytosolic). A number of pieces of evidence point to the role of 
mitochondrial NAD+-specific isocitrate dehydrogenase in the regulation of the rate of 
mitochondrial assembly besides its specific role in the TCA cycle [2]. The formation of 
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succinate is catalyzed by -ketoglutarate dehydrogenase (4), which promotes the oxidative 
decarboxylation of -ketoglutarate via succinil–CoA to succinate, which is then converted to 
fumarate by succinate dehydrogenase (5). The next step of the TCA cycle is the conversion 
of fumarate to malate by the enzyme fumarase (6), which exists as separate cytosolic and 
mitochondrial forms. There is not yet a clear explanation for the existence of these two 
forms; however, the localization and distribution of fumarase appears to be unique because 
there is only one translation product, which is targeted to mitochondria [3]. Malate 
dehydrogenase (7) catalyzes the last step of the TCA and leads to the oxidation of malate to 
oxaloacetate. There are three isoenzymes of malate dehydrogenase: a cytosolic, a 
mitochondrial and a peroxissomal one; however, the mitochondrial one accounts for 90% of 
malate dehydrogenase activity when glucose is being metabolized [4]. 
TCA cycle flux appears to be constricted at two steps on the basis of the limited availability 
of the substrates oxaloacetate and -ketoglutarate. The genes encoding TCA proteins might 
also be regulated by glucose levels. In S. cerevisiae the depletion of glucose increases 3–10 
times the TCA messenger RNAs [5]. Oxygen limitation could also induce a shift in the TCA 
cycle, which operates as a cycle during aerobic growth [6]. 
All reactions of glycolysis take place in the cell  cytosol. The citric acid cycle and the 
respiratory chain are located within mitochondrial matrix. In contrast with all of the other 
enzymes of the TCA cycle, which are soluble proteins found in the mitochondrial matrix, 
succinate dehydrogenase (SDH) is an integral membrane protein tightly associated with the 
inner mitochondrial membrane [7]. Membrane-bound succinate dehydrogenase (EC 
1.3.99.1) or succinate-coenzyme Q reductase or Complex II, is present in all aerobic cells. It 
was discovered by Thunberg in 1909. Now we know that  SDH has several particularly 
interesting properties: (1) it is a membrane-bound dehydrogenase linked to the respiratory 
chain and a member of the tricarboxylic acid (TCA) cycle; (2) its activity is modulated by 
several activators and inhibitors; and (3) it is a complex enzyme, and covalently bound 
flavin adenine dinucleotide (FAD) [8]. 
2. SDH structure 
SDH is a heterotetramer composed of flavoprotein (Fp) of about 70 kDa, an iron-sulfur 
protein (Ip) of about 30 kDa, and two hydrophobic anchoring subunits of 7-17 kDa. The Fp 
contains the active site and the unusual cofactor, an 8α-N(3)-histidyl-FAD linked at a 
conserved histidine residue (Figure 2).  
FAD attachment is stimulated by, but not dependent upon, the presence of the iron-sulfur 
subunit and citric acid cycle intermediates such as succinate, malate, or fumarate [9].  
The Ip subunit contains three different iron-sulfur clusters: [2Fe-2S], [3Fe-4S], and [4Fe-4S] 
(Figure 3).  
These clusters are coordinated by conserved cysteine residues: [2Fe-2S] (Cys-67, Cys-72, 
Cys-75, Cys-87); [4Fe-4S] (Cys-159, Cys-162, Cys-165, Cys-226) and [3Fe-4S] (Cys-169, Cys-
216, Cys-222) [10]. 
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Figure 2. The covalent bond between FAD and succinate dehydrogenase. 
 
Figure 3. The 2Fe-2S cluster of succinate dehydrogenase [9]. 
The hydrophobic anchoring subunits are integral membrane proteins and interact with 
quinone substrates. The yeast and mammalian SDH also contains a b-type heme. Oyedotun 
et al. [11] demonstrated the presence of an amount of cytochrome b562 steichiometric to 
covalent FAD. Together, the Fp and Ip form a catalytic dimer that is attached to the 
membrane by the anchoring subunits, thereby composing the holoenzyme. In yeast, the 
SDH Fp, Ip, and two anchoring subunits are encoded by the nuclear genes, SDH1, SDH2, 
SDH3, and SDH4, respectively, which have all been cloned and sequenced. The SDH 
subunits are translated in the cytoplasm, targeted to mitochondria by cleavable amino-
terminal presequences, translocated across both mitochondrial membranes, and finally 
assembled with each other and their respective co-factors into a functional complex [10].  
The quaternary structure model of the SDH for different cells, e.g. S. cerevisiae and 
mammalian, was described in study conducted by Oyedotun and Lemire [10] and 
Yankovskaya et al. [12]. First subunit of SDH provides the binding site for the oxidation of 
succinate. The side chains Thr254, His354, and Arg399 stabilize the molecule while FAD 
oxidizes and carries the electrons to the first of the iron-sulfur [2Fe-2S] clusters. Whereas, 
ubiquinone binding site is located is in a gap composed of three SDH subunits. Ubiquinone 
is stabilized by the side chains of His207 of second subunit, Ser27 and Arg31 of third subunit 
C, and Tyr83 of fourth subunit. The quinine ring is surrounded by Ile28 of third subunit and 
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Pro160 of second subunit B. These residues, along with Il209, Trp163, and Trp164 of second 
subunit B, and Ser27 (C atom) of third subunit, form the hydrophobic environment of the 
quinine binding pocket. The succinate binding site and ubiquinone binding site are 
connected by a chain of redox centres including FAD and the iron-sulfur clusters. This chain 
extends over 40 Å through the enzyme monomer with an edge-to-edge distance between the 
centres is less that 14 Å limit for physiological electron transfer [8, 11].  
In the place for heme b, the N 2 atom of Sdh3p His106 and the S  atom of Sdh4p Cys78 are 
correctly oriented to form coordinating bonds with the central iron atom of the heme. The 
distance between the iron atom and the N 2 atom is 2.21 Å, but  the S  atom of Cys78, the 
putative second heme axial ligand, is 2.96 Å away from the heme Fe. UQ can be docked into 
two spatially separated sites with an edge-to-edge distance of 25.4 Å. The new amino acid 
residues that may determine the structural or catalytic properties of each of the two quinone 
binding sites were identified. The model also provided insight into the unusual use of a 
cysteine (Sdh4p Cys78) as the second heme ligand instead of the histidine residues [10].  
3. SDH function and regulation 
Succinate dehydrogenase is a key enzyme in intermediary metabolism and aerobic energy 
production in living cells. This enzymes catalyses the oxidation of succinate into fumarate in 
the Krebs cycle (1), derived electrons being fed to the respiratory chain complex III to reduce 
oxygen and form water (2). This builds up an electrochemical gradient across the 
mitochondrial inner membrane allowing for the synthesis of ATP. Alternatively, electrons 
can be diverted to reduce the ubiquinone pool (UQ pool) and provide reducing equivalents 
necessary to reduce superoxide anions originating either from an exogenous source or from 
the respiratory chain itself (3) [13] (Figure 4). 
 
Figure 4. The functions of the succinate dehydrogenase in the mitochondria [13]. 
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In the reaction of oxidation of succinate to fumarate, two hydrogen atoms are removed from 
substrate by flavin adenine dinucleotide (FAD), a prosthetic group that is tightly attached to 
succinate dehydrogenase (Figure 5).  
 
Figure 5. The succinate dehydrogenase reaction. 
Two electrons from the reduced SDH-FADH2 complex are then transferred to ubiquinone 
(Q), a soluble component of the electron transport system complex II. Ubiquinone is then 
reduced to ubiquinol ( QH2). 
Flavin adenine dinucleotide (FAD) is an essential cofactor for SDH enzyme. The generation 
of adenosine triphosphate (ATP) in mitochondria is coupled to the oxidation of 
nicotinamide adenine dinucleotide (NADH) and FADH2 and reduction of oxygen to water 
within the respiratory chain and a three-dimensional structure of the mitochondrial 
respiratory membrane protein complex II. FAD attachment is stimulated by, but not 
dependent upon, the presence of the iron-sulfur subunit and citric acid cycle intermediates 
such as succinate, malate, or fumarate [9]. The substrate analog malonate is a competitive 
inhibitor of the succinate dehydrogenase complex. Malonate, like succinate, is a 
dicarboxylate that binds to cationic amino acid residues in the active site of the succinate 
dehydrogenase complex. However, malonate cannot undergo oxidation because it lacks the 
-CH2 - CH2- group necessary for dehydration. To study the effects of a competitive 
inhibitior on the activity of succinate dehydrogenase, malonate will be added to a reaction 
mixture; malonate is sufficiently different from succinate that it cannot de dehydrogenated, 
i.e. malonate is not metabolized [8, 14]. 
SDH is a difficult enzyme to extract from respiratory membrane whilst still retaining its in 
vivo properties. Most of the extraction procedures used in early work were rather drastic 
and yielded soluble preparations of rather dubious integrity. However, the recent 
introduction of a more gentle method, involving disruption of the membrane with 
chemotropic agents, has yielded an active and nearly homogeneous enzyme of relatively 
low molecular weight (97,000). This enzyme can be separated by freezing and thawing into 
two inactive subunits. One of these, an iron sulphur flavoprotein of molecular weight 
70,000, contains one mole of FAD and four moles each of iron and labile sulphide per mole 
of protein; The other, an iron-sulphur protein of molecular weight 27,000, also contains four 
moles each of iron and labile sulphide.  It was determined that the large subunit of SDH is 
essential for catalytic activity, but the function of the small subunit, be it catalytic or 
regulatory [8].  
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Electronic paramagnetic resonance measurements of SDH components indicated that at 
least three separate centres are present. The S-3 centre (E'o = +60 mV) is a high potential Fe-S 
protein and is probably identical with the 4Fe-rS centre of low molecular weight subunit. 
Centres S-1 and S-2 (E'o = +15 mV and -260 mV respectively), are of the 2Fe-2S ferredoxin 
type and are probably associated with a larger, flavin containing subunit. Thus, electron 
transfer from succinate to ubiquinone probably occurs in the sequence: FAD, S-1, S-3. The 
redox potential of S-2 is rather too low to allow this centre to be catalytically active in the 
forward direction [8,15]. 
The catalytic activity of succinate dehydrogenase is modulated both by post translational 
phosphorylation/acetylation and active site inhibition. For example, phosphorylation of the 
Sdh1 subunit leads to attenuate activity of SDH. The activity of this enzyme may be also 
modulated by Krebs cycle intermediates including oxaloacetate or malonate which are 
strong inhibitors. Mechanisms of inhibition by these compounds differ significantly because 
oxaloacetate, a competitive inhibitor of succinate dehydrogenase, bounds with a sulfhydryl 
group of the enzyme to abolish the enzyme activity [16]. It is known that SDH is sensitive to 
different thiol-binding reagents. Inhibition of the enzyme by these kinds of reagents resulted 
from the modification of a sulfhydryl group located at the active site. This thiol, although 
not essential for substrate binding or catalysis, could influence the binding of 
dicarboxylates, probably by steric hindrance when a larger group or a charged group were 
attached to it. The inhibition of SDH by histidine specific reagents was also reported, and 
the participation of an imidazole ring in the initial step of succinate oxidation was 
suggested. The inactivation of SDH by phenylglyoxal and 2,3 –butanedione showed the 
presence of an arginine-residues  that interacts with dicarboxylate to form the primary 
enzyme-substrate complex [17].  
SDH is not only known to catalyse a unique reaction, which requires the participation of its 
four subunits, but deleterious mutations in any of the SDH genes should invariably result in 
a decreased SDH activity. Therefore, the striking phenotypic differences associated with 
mutations in the four subunits raise puzzling questions. SDH also plays a specific role in the 
maintenance of the mitochondrial UQ pool reduction. Ubiquinone, beside its function as an 
electron carrier mediating electron transfer, is admittedly working as a powerful antioxidant 
in biological membranes. Then, only a portion of the UQ pool may be actually involved in 
electron transfer depending on dehydrogenases involved. Accordingly, the measurable 
redox status of the UQ pool should result from the reducing activity of the different 
dehydrogenases, the oxidising activity of complex III and the kinetic equilibrium in the 
pool. The UQ pool therefore represents an electron sink and, when reduced, an antioxidant 
reservoir in the mitochondrial inner membrane. However, UQ is a double-faced compound, 
possibly working as either an antioxidant when fully reduced to ubiquinol, or a pro-oxidant 
when semi-reduced to the unstable ubisemiquinone form. Possibly together with reduced 
cytochrome b, semi-reduced quinones constitute the prominent source of superoxides. 
Finally, when defective, the abnormal amount of superoxides can be produced, e.g.  flavin 
radicals of complex I. Delivering electrons for the full reduction of UQ to UQH2 might then 
be of a tremendous importance for the control of oxygen toxicity in the mitochondria. 
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Therefore, the SDH, thanks to its unique redox properties, may be a key enzyme to control 
UQ pool redox poise under these conditions [13]. 
Also mutations in genes encoding SDH subunits lead to reduced activity of SDH enzyme. 
The yeast cells disrupted in SDH2 (sdh2Δ) showed dramatically accumulate succinate 
resulting in inhibition of at least two α-ketoglutarate dependent enzymes that generate 
succinate as a by-product. Disruption of complex II activity should alter TCA cycle 
metabolite levels in the mitochondrial matrix. It was found that neither sdh1Δ, nor sdh2Δ 
cells have measurable SDH activity. The succinate accumulates to 8-fold higher levels in 
sdh2Δ cells relative to wild-type cells. Furthermore, complex II + III activity was completely 
abolished in both SDH mutants without a corresponding compensation in NADH 
dehydrogenase activity. As a result, complex IV activity was decreased in the SDH mutants 
[18] (Figure 6). 
 
Figure 6. Relative concentration of main metabolities of TCA cycle for sdh1Δ, nor sdh2Δ yeast cells [18]. 
4. SDH activity assay 
The succinate is the most efficient energy source, so the SDH activity assay can be an 
important method for measurement of the yeast vitality in scope to control, e.g. different 
fermentation processes [19].  SDH activities can be measured in vitro in cell lysates or in 
mitochondrial fraction as well as in situ in individual cells. Since SDH is bound to the inner 
membrane, it is easily isolated along with the mitochondria by different techniques: sucrose 
density gradient ultracentrifugation, free-flow electrophoresis or a commercially available 
kit-based method [20]. The mitochondrial fraction is the source of the enzyme. Since none of 
the key components can be measured directly, the reaction succinate → fumarate is 
measured by monitoring the reduction of an artificial electron acceptor. To use an artificial 
electron acceptor, the normal path of electrons through the mitochondrial electron transport 
system must be blocked. This is accomplished by adding either sodium azide or potassium 
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cyanide to the reaction mixture. These poisons inhibit the transfer of electrons from 
cytochrome a3 to the final electron acceptor, oxygen, thus electrons cannot be passed along 
by the preceding cytochromes and coenzyme Q. Instead, the electrons from SDH-FADH2 
can be picked up by an artificial electron acceptor, such as the dye 
2,6dichlorophenolindophenol (DCIP). The reduction of DCIP can be followed 
spectrophotometrically since the oxidized form of the dye is blue and the reduced form is 
colorless. This reaction can be summarized as 
SDH-FADH2 + DCIPoxid.  →  SDH-FAD + DCIPred. + 2H+  
The change in absorbance, measured at 600 nm, can be used to follow the reaction over time 
[21]. To use an artificial electron acceptor, the normal path of electrons in the electron 
transport chain must be blocked. This is accomplished by adding either potassium cyanide 
or sodium azide to the reaction mixture. The rate of the disappearance of the blue color is 
proportional to the concentration of enzyme. The change in absorbance of the mixture is 
measured as a function of time and the enzyme concentration is determined from these data. 
Enzymatic reactions in yeasts are usually studied in cell-free extracts which requires 
disruption of cells and as consequence, inactivation of particular enzymes often can be 
observed. Generally we can conclud that determination of SDH enzyme activity has proved 
to be a difficult enzyme to extract from respiratory membrane whilst still retaining its in vivo 
properties. Most of the described extraction procedures were rather drastic and yielded 
soluble preparations of rather dubious integrity [8].  
In recent years quantitative histochemical procedures has been proved to be a powerful 
research tool, especially in microphotometric assessment in situ of the specific activity of 
dehydrogenases in individual cells. These assays are simple and valid alternative to 
conventional biochemical techniques. Methods in situ can provide the cellular resolution 
necessary to determine enzyme-specific activities not only in whole cell preparations but 
also in distinct subcellular compartments [19].  
Reduction of various tetrazolium salts by dehydrogenases of metabolically active cells leads 
to production of highly colored end products – formazans (Figure 7). The history of the 
tetrazolium salts and formazans goes back 100 years, to when Friese (1875) reacted benzene 
diazonium nitrate with nitromethane, to produce a cherry-red "Neue Verbindung". This was 
the first formazan. Nineteen years later, Von Pechmann and Runge (1894) oxidised a 
formazan to produce the first tetrazolium salt [21].  
 
Figure 7. Tetrazolium salt and its coloured formazan. 
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Many hundreds of tetrazolium salts and formazans were prepared in the following years, 
but only a handful have found applications in biological research.There is a wide range of 
tetrazolium salts commonly used in the field of microbiology from the classical ones to the 
new generation of its derivatives. Among them are: blue tetrazolium chloride (BT),  2,3,5-
triphenyl tetrazolium chloride (TTC), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), 5-cyano-2,3-ditolyl tetrazolium chloride (CTC), 2,3-bis(2-methoxy-4-nitro-5-
sulphophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT),  4-[3-(4-
idophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST1), 2-(p-
iodophenyl)-3(p-nitrophenyl)-5-phenyltetrazolium chloride (INT) or 2,2'-dibenzothiazolyl-
5,5'-[4-di(2-sulfoethyl)carbamoylphenyl]-3,3'-(3,3'-dimethoxy-4,4' biphenyl) ditetrazolium, 
disodium salt (WST-5) [19, 22, 23].  
In the case of enzymatic reaction conducted in situ the plasma membrane forms a barrier 
with low degree of penetration. Therefore, cell permeabilization, e.g. by digitonin, is 
recommended as an alternative method for the study of intracellular enzyme activities. 
According to the results obtained by Berlowska et al. [23] digitonin was effective in 
membrane permeabilization without negative influence on cell morphology. After digitonin 
treatment, the visible formazan crystals were observed inside the yeast cells, but not outside 
them (Figures 8-10 A, B).  
The formazan products are water-insoluble, but readily diffuses out of yeast cells after 
solubilization in DMSO. Good correlation (R2=0,97) between BTf absorbance intensity after 
DMSO extraction and number of yeast cells was seen. Linear correlation was observed in the 
concentration range of yeast cells from 9107 to5108 per sample. For yeast cell 
concentrations below 1107 per sample the formazan color intensity signals were too low to 
detect with good precision. The results obtained for SDH activity were in good agreement  
 
Figure 8. Yeast cells after reaction with blue tetrazolium chloride (BT). A – without permeabilization; B 
– with permeabilization by 0.05% digitonin. Images of light microscopy. 
(A) (B)
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Figure 9. Yeast cells after reaction with 2,3,5-triphenyl tetrazolium chloride (TTC). A – without 
permeabilization; B – with permeabilization by 0.05% digitonin. Images of fluorescence microscopy. 
 
Figure 10. Yeast cell after reaction with 2,3,5-triphenyl tetrazolium chloride (TTC). A – without 
permeabilization; B – with permeabilization by 0.05% digitonin. Images of scanning microscopy. 
with that of ATP content in yeast cells. Significant decreasing of succinate dehydrogenase 
activity and ATP content were observed during aging of tested yeast strains [19, 23]. 
5. The role of SDH in human disease 
Saccharomyces cerevisiae is a simple eukaryotic organism, with a complete genome sequence. 
Many genetic tools that have been created during these years, including the complete 
(A) (B)
(A) (B)
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collection of gene deletions and a considerable number of mechanisms and pathways 
existing in higher eukaryotes was first studied and described in yeast. Moreover, about 40% 
of human genes whose mutations lead to diseases have an orthologue in yeast and genomic 
screens have been extended to mitochondrial diseases. The study of mitochondrial functions 
and dysfunction is of special interest in yeast because it is in this organism that 
mitochondrial genetics and recombination have been discovered and that 
nucleomitochondrial interactions have been studied in-depth. There are also specific reasons 
for choosing S. cerevisiae for mitochondrial studies. This organism is petite-positive, which 
can successfully grow in the absence of oxygen. Therefore it can lose its mitochondrial 
genome provided it is supplied with a substrate for fermentation. Consequently, all 
mutations of the mitochondrial genome can be studied without cell lethality. The frequency 
of homologous recombination is very high (1% recombination is considered to correspond 
to about 100 bp in the mitochondrial genome). It is genetically easy to transfer mitochondria 
from one nuclear genetic background to another via karyogamy. Additionally, mitochondria 
can be transformed making in vitro mutation analysis possible. The richness and ease of 
yeast molecular genetics opens big opportunities, and even the major difference existing 
between human and yeast mitochondrial genomes, i.e. the predominant heteroplasmy of 
human and the homoplasmy of yeast, can result in the easier definition of the pathogenic 
mutations. To review mitochondrial diseases may be a very difficult task because the 
definition might include different kinds of metabolic disorders or degenerative syndromes 
[24]. Moreover, some important aspects have been extensively reviewed and the reader 
might refer to very good recent articles by DiMauro and Garone [25] for historical aspects, 
by Wallace et al. [26, 27] for bioenergetics, by Spinazzola and Zeviani [28] for nucleo–
mitochondrial intergenomic cross-talk. The previous review by Schwimmer et al. [29] was 
given an important outline of yeast models of mitochondrial diseases. SDH in yeast and 
human are very similar. They are composed of four subunits (SDHA-D, like SDH1-4 in 
yeast), all encoded by nuclear genes.  
In the last ten years, deficiencies in TCA cycle enzymes have been shown to cause a wide 
spectrum of human diseases. For instance, mutation in the gene encoding fumarase is a rare 
cause of encephalomyopathy and a far more common cause of leiomyomas of the skin and 
uterus and of renal cancer (Table 1). 
The TCA path dysfunction may also result from concurrent impairments in several steps of 
the cycle. The combined deficiencies in SDH and aconitase was observed in Friedreich’s 
ataxia [22, 39]. Measures in autopsied brains from Alzheimer’s Disease (AD) patients reveal 
a decrease in the activity of α-ketoglutarate dehydrogenase complex (KGDHC) and an 
increase in malate dehydrogenase (MDH) activity [33]. The ratios between TCA enzymes are 
consistent for each mammalian tissues presumably reflecting their metabolic demand. 
Consequently, in addition to the determination of residual absolute activities, estimation of 
ratios between enzyme activities is an effective means of detecting partial but potentially 
harmful deficiencies. When used to assess respiratory chain activities, this approach enabled 
the identification of several gene mutations, even in patients with partial respiratory chain 
deficiencies. At present, TCA enzyme activities are measured using a series of independent  
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Enzyme Clinical presentation References 
Fumarase 
Progressive encephalopathy 
Hereditary leiomyomatosis and renal cell 
cancer 
[30] 
[31] 
Malate dehydrogenase Alzheimer’s disease  [32, 33] 
Citrate synthase No disease identified so far  
Aconitase No disease identified so far  
Isocitrate dehydrogenase Low-grade gliomas [34] 
-Ketoglutarate 
dehydrogenase 
Congenital lactic acidosis [35] 
Succinyl-CoA ligase 
Encephalomyopathy with mtDNA 
depletion 
[36] 
Succinate 
dehydrogenase 
Encephalopathy (Leigh syndrome) 
Pheochromocytoma and paraganglioma 
[37] 
[38] 
Table 1. Primary deficiencies in TCA cycle enzymes in humans [22]. 
assays that are both laborious and time-consuming. The limited set of assays allowing both 
measurement of all TCA enzyme activities and detection of abnormalities in enzyme activity 
ratios were developed. These assays were used successfully to detect severe and partial 
isolated deficiencies in several TCA enzymes. The first assay measures succinyl-CoA ligase, 
SDH, glutamate dehydrogenase (GDH), fumarase, and malate dehydrogenase. This assay 
was performed in medium containing 50 mM KH2PO4 (pH 7.2) and 1 mg/ml BSA. The 
reduction of DCPIP was measured using two wavelengths (600 nm and 750 nm) with 
various substrates and the electron acceptors decylubiquinone and phenazine methosulfate. 
The second assay measured -ketoglutarate dehydrogenase, aconitase, and isocitrate 
dehydrogenase activities. The pyridine nucleotide (NAD+/NADP+) reduction is measured 
with various substrates using wavelengths of 340 nm and 380 nm. In the third assay, citrate 
synthase was measured by monitoring dithionitrobenzene (DTNB; Ellman’s reagent) 
reduction at wavelengths of 412 nm and 600 nm [22].  
The deleterious mutations in any of the SDH genes should invariably result in a decreased 
SDH activity [13]. Hence, SDH 'inactivation' induces abnormal stimulation of the hypoxia-
angiogenesis pathway. Therefore, the striking phenotypic differences associated with 
mutations in the four subunits raise puzzling questions. It has been reported that inherited 
deficiencies of SDH associated with presence of mutant protein Fp are always associated 
with relatively high residual activities, ranging from 25-50% of control mean values. As a 
comparison, less than 5% residual activity is frequently measured in patients with severe 
defect of complex IV or complex I. The mutations in any of the SDH cause the complex II to 
fully disassemble. When complex II is absent, it can be disregarded as a source of additional 
superoxide production. Thus, the superoxide overproduction would lead to tumour 
formation that should be ascribed to the decreased ability of the SDH to adequately reduce 
the Q pool, a necessary condition to resist oxidative stress [8].  
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Ubiquinone, beside its function in the respiratory chain as an electron carrier mediating 
electron transfer between the various dehydrogenases and the cytochrome path, is working 
as a powerful antioxidant in biological membranes [13]. It is possibly for this exact reason in 
much larger amounts compared to other electron carriers of the respiratory chain, including 
the sum of the dehydrogenases. When it is defective, the respiratory chain can produce an 
abnormal amount of superoxides involving additional respiratory chain components such 
as flavin radicals of complex I. Delivering electrons for the full reduction of Q to QH2 might 
then be of a tremendous importance for the control of oxygen toxicity in the mitochondria. 
Therefore, the SDH is a key enzyme to control Q pool redox poise under these conditions, 
due to its unique redox properties [8]. 
Iron-sulfur (Fe-S) proteins facilitate multiple functions, including redox activity, enzymatic 
function, and maintenance of structural integrity. More than 20 proteins are involved in the 
biosynthesis of iron-sulfur clusters in eukaryotes. Defective Fe-S cluster synthesis not only 
affects activities of many iron-sulfur enzymes, such as aconitase and succinate 
dehydrogenase, but also alters the regulation of cellular iron homeostasis, causing both 
mitochondrial iron overload and cytosolic iron deficiency. Fe-S cluster biogenesis takes 
place essentially in every tissue of humans, and products of human disease genes have 
important roles in the process [40]. 
Succinate is an oxygen sensor in the cell and can help turn on specific pathways that 
stimulate cells to grow in a low-oxygen environment (hypoxia). In particular, succinate 
stabilizes a protein called hypoxia-inducible factor (HIF) by preventing a reaction that 
would allow HIF to be broken down. HIF controls several important genes involved in cell 
division and the formation of new blood vessels in a hypoxic environment. Mutations in 
genes encoding SDH subunits have been linked to severe encephalopathy and, more 
recently, to familial paraganglioma (PGL) and pheochromocytoma (PHEO) (PHEO: adrenal 
gland PGL). Isolated complex II deficiency is a very rare condition, occurring in 
approximately 2–4% of all respiratory chain enzyme deficiencies. At least three mutations in 
the SDH genes have been identified in people with PGL or PHEO, which are noncancerous 
(benign) tumors associated with the nervous system. SDHB-D gene mutations are seen most 
commonly in people with PGL, but they were found in people with PHEO. However, a 
single mutation in the SDHA gene increases the risk that an individual will develop the 
condition, and additional mutation that deletes the normal copy of the gene is needed to 
cause tumor formation. This second mutation, called a somatic mutation, is acquired during 
a person's lifetime and is present only in tumor cells. The SDH genes mutations associated 
with nonsyndromic PGL or PHEO change single protein building blocks (amino acids) in 
the SDH protein sequence or result in a shortened protein. As a result, there is little or no 
SDH enzyme activity. Because the mutated SDH enzyme cannot convert succinate to 
fumarate, succinate accumulates in the cell. The excess succinate abnormally stabilizes HIF, 
which also builds up in cells. Excess HIF stimulates cells to divide and triggers the 
production of blood vessels when they are not needed. Rapid and uncontrolled cell division, 
along with the formation of new blood vessels, can lead to the development of tumors. 
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Mutations in the SDHA gene were identified in a small number of people with Leigh 
syndrome, a progressive brain disorder that typically appears in infancy or early childhood. 
Affected children may experience vomiting, seizures, delayed development, muscle 
weakness, and problems with movement. Heart disease, kidney problems, and difficulty 
breathing can also occur in people with this disorder. The one child died suddenly at the age 
of five months from a severe deterioration of neuromuscular, cardiac, and hepatic 
symptoms after an intermittent infection. The SDHA gene mutations responsible for Leigh 
syndrome change single amino acids in the SDHA protein or result in an abnormally short 
protein. These genetic changes disrupt the activity of the SDH enzyme, impairing the ability 
of mitochondria to produce energy. Further studies showed that several patients with 
complex II deficiency do not have mutations of SDHA. This suggested a role of additional 
nuclear genes involved in synthesis, assembly, or maintenance of SDH.  It is not known, 
however, how mutations in the SDHA gene are related to the specific features of Leigh 
syndrome [41, 42]. 
Two plausible hypotheses have been proposed to explain the peculiar linkage between 
disruption of electron flow through mitochondrial complex II and tumorigenesis in 
neuroendocrine cells. In the reactive oxygen species (ROS) hypothesis, it is proposed that an 
intact, catalytically active SDHA subunit generates genotoxic ROS by uncoupled electron 
flow from succinate to oxygen or water in cells where one of the electron-carrying subunits 
(SDHB, SDHC or SDHD) is missing or inactive. The ROS model implies that genotoxic ROS 
mutagenize nuclear proto-oncogenes or tumor suppressors (Figure 11). This model predicts 
that ROS should be increased in cells lacking SDHB, SDHC or SDHD, but not when SDHA 
is missing. Although certain mutations in these genes result in ROS production in 
Saccharomyces cerevisiae and mammalian cell lines, it is not clear that ROS accumulate to 
levels that are mutagenic. 
 
Figure 11. ROS model [18]. 
In the succinate accumulation hypothesis, the loss of SDHB results in loss of SDH activity 
and causes succinate accumulation (Figure 12). 
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Figure 12. Succinate accumulation model [18]. 
Excess succinate is shuttled from the mitochondrial matrix to the cytoplasm, where it 
inhibits any of several aKG-dependent enzymes (E) that regulate levels or activities of 
important regulatory proteins (black box). The loss or inactivation of SDHB, C or D proteins 
yields a catalytically inactive SDHA subunit, resulting in blockade of the TCA cycle and 
diffusion of accumulated succinate to the cytoplasm. Succinate can then act as an inhibitor 
of a-ketoglutarate-dependent enzymes that use ferrous iron and molecular oxygen as 
cofactors to hydroxylate their substrates and generate succinate as a product. It has been 
demonstrated that two a-ketoglutarate -dependent enzymes, the prolyl hydroxylases, are 
inhibited by succinate accumulation in cells that have lost SDHD function. Smith et al [18] 
reported that yeast cells disrupted in SDH2 (sdh2Δ) show increased in ROS production and 
protein oxidation without detectable increase in DNA damage. More strikingly, sdh2Δ cells 
dramatically accumulate succinate resulting in inhibition of at least two aKG-dependent 
enzymes that generate succinate as a by-product [18]. 
6. Metabolic engineering of yeast SDH for the biotechnological processes 
Metabolic engineering, i.e., the intentional redirection of metabolic fluxes, plays an 
exceptional role in improving yeast strains for all industrial applications. In contrast to 
classical methods of genetic strain improvement such as selection, mutagenesis, mating, and 
hybridization, metabolic engineering confers two major advantages: (1) the directed 
modification of strains without the accumulation of unfavorable mutations and (2) the 
introduction of genes from foreign organisms to equip S. cerevisiae with novel traits. The 
latter is particularly crucial for industrial biotechnology to provide pathways that extend the 
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spectrum of usable industrial media (e.g., lignocellulosic biomass) and/or to produce 
compounds not naturally formed by S. cerevisiae. Since the first introduction of metabolic 
engineering, there have been tremendous enhancements of its toolbox, and several related 
disciplines have emerged, such as inverse metabolic engineering and evolutionary 
engineering. These developments have strongly influenced yeast strain improvement 
programs in the past few years and have greatly enhanced the potential for using yeast in 
biotechnological production processes [43].  
The main goals of metabolic engineering can be summarized in the following four 
categories: (1) improvement of yield, productivity and overall cellular physiology, (2) 
extension of the substrate range, (3) deletion or reduction of by-product formation and (4) 
introduction of pathways leading to new products. Commonly these goals can be achieved 
by a three-step procedure. Firstly, a genetic modification is proposed, based on metabolic 
models. After genetic modification, the recombinant strain is analysed and the results are 
then used to identify the next target for genetic manipulation, if necessary. Thus, the 
construction of an optimal strain involves a close interaction between synthesis and analysis, 
usually for several consecutive rounds. The rapid development and frequent success in this 
field is demonstrated by the large number of reviews about the theoretical and practical 
aspects of metabolic engineering. Knowledge of cellular and microbial physiology, as well 
as the underlying metabolic networks or enzymes, is an important prerequisite for 
successful engineering. A new term, ‘inverse metabolic engineering’ (IME) coins to 
encompass the construction of strains with a particularly desirable physiological phenotype, 
e.g. enhanced production of heterologous protein [44].  
Recently, a computational approach for the identification of every possible biochemical 
reaction from a given set of enzyme reaction rules was reported. This analysis suggested 
that the native pathways are thermodynamically more favorable than the alternative 
possible pathways. The pathways generated involve compounds that exist in biological 
databases, as well as compounds that exist in chemical databases and novel compounds, 
suggesting novel biochemical routes for these compounds and the existence of biochemical 
compounds that remain to be discovered or synthesized through enzyme and pathway 
engineering [45]. 
Due to its importance in traditional biotechnology such as baking, brewing, and wine 
making, research activities historically have focused on the yeast Saccharomyces cerevisiae. It 
is relatively tolerant to low pH values and high sugar and ethanol concentrations, i.e., 
properties which lower the risk of contamination in industrial fermentation. These features 
are the major reasons for increasing S. cerevisiae exploration in industrial (“white”) 
biotechnology, focusing on the fermentative production of industrially relevant 
biochemicals, e.g., glycerol, propanediol, sugar alcohols, organic acids, etc. Among these 
compounds, several organic acids may fulfill a role as platform molecules using their 
(multiple) functional groups as a target for enzymic or chemical catalysis [43].  
In the United States were identified 10 organic acids as key chemical building blocks [44]. 
Similarly, the European focus group BREW identified 21 key compounds that can be 
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produced from different, including renewable sources, a number of which were organic 
acids [45]. One example of such a chemical is succinic acid. Succinic acid is used as a 
surfactant, detergent or foaming agent, as an ion chelator, and also in the food industry as 
an acidulant, flavoring agent or anti-microbial agent, as well as in health-related products 
(such pharmaceuticals and antibiotics). Currently, it is produced from petrol and is too 
expensive to be used as a general building-block chemical. However, provided that its price 
becomes competitive, succinic acid could replace petrol-derived maleic anhydride in 
chemical synthesis processes in the future [46-47]. Similar chemical derivatizations can be 
applied to malic and fumaric acid, so that they can also be considered interesting C4 
building blocks [48-53]. 
The chemical behavior of the dicarboxylic acid – succinic acid is determined principally by 
its two carboxyl groups. This substance is either directly utilized in the pharmaceutical or 
chemical industry or represent building block or precursor for further chemical or 
enzymatic syntheses. The following reactions and derivatives are considered interesting: (1) 
reductions of succinic acid to 1,4-butanediol, -butyrolactone, tetrahydrofuran and its 
derivatives; (2) reductive amination of succinic acid or -butyrolactone to pyrrolidiones; (3) 
polymerization of succinic acid with diols (building block of polyesters); (4) polymerisation 
of succinic acid with diamines to form polyamides, etc. The examples of the substances that 
can be derived from succinic acid are shown in table 2.  
Butanediol, tetrahydrofuran and -butyrolactone, are standard substances for the chemical 
industry. These are used as solvents, as well as for fiber and polymer production. 
Dimethylsuccinate is one of the so-called dibasic esters that have great potential as solvents 
with environmentally benign characteristics. Thus, the potential market volume for succinic 
acid is high, fuelling substantial efforts to establish a microbial process for succinic acid 
production [47]. 
The chemical synthesis of succinic acid is predominantly based on maleic anhydride and 
requires heavy metal catalysts, organic solvents, high temperatures and high pressures. It 
makes the conversion of maleic anhydride to succinic acid costly and ecologically 
questionable [49]. On the other hand, succinate is produced naturally by many 
microorganisms as an intermediate of the central metabolism or as a fermentation end 
product.  
The succinate producers include bacterial strains, e.g. Mannheimia succiniproducens [54]. 
However, none of these microorganisms are currently used in industry. Some prokaryotes  
 
No Name Chemical structure Examples of uses 
1 1,4 -Diaminobutane 
 
Used for polyamide 
production 
2 Succindiamide 
 
Used as anticonvulsant 
drugs and to form covalent 
bonds between proteins or 
peptides and plastics 
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No Name Chemical structure Examples of uses 
3 1,4 – Butanediol (BDO) 
 
Replacement of fossil-
derived BDO by bio-based 
BDO in polybutylene 
tereftalate (PBT) 
Replacement of fossil-
derived BDO by bio-based 
BDO in polybutylene 
succinate (PBS) 
4 Succinonitrile  
Precurser for industrial 
production of polyamides 
5 Dimethylsuccinate 
Used as fuel oxygenates and 
as green solvents 
6 
N-methyl-pyrolidone 
(NMP) 
 
Replacement of fossil-
derived NMP by bio-based 
NMP; NMP is an important, 
versatile solvent for  the 
chemical industry 
8 2-Pyrolidone As above 
7 -Butyrolactone (GBL) 
 
Replacement of fossil-
derived BGL by bio-based 
BGL ; BGL is important as 
an intermediate in the 
manufacture of pyrrolidone 
derivatives and as a solvent 
for polymers and 
agrochemicals 
9 Tetrahydrofuran (THF) 
 
Replacement of fossil-
derived THF by bio-based 
THF ; THF is mainly used as 
a solvent and as an 
intermediate in the 
production of thermoplastic 
polyurethanes, elastic fibers 
etc. 
Table 2. Examples of various substances that can be derived from succinic acid by chemical conversion 
[47]. 
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have complex medium requirements and they are generally unable to grow and produce 
organic acids at the low pH values.  These restrictions provide strong incentives to integrate 
and optimize succinate production pathways in other microorganisms via metabolic 
engineering approaches. 
The popularity of S. cerevisiae in basic and applied research is undoubtedly influenced by its 
classification as GRAS (generally regarded as safe) by the U.S. Food and Drug 
Administration (FDA). Baker’s yeast S. cerevisiae was the first eukaryotic organism in which 
complete genomic sequence was determined. Several databases such as the Saccharomyces 
Genome Database (http://www.yeastgenome.org/) and the Comprehensive Yeast Genome 
Database (http://mips.gsf.de/genre/proj/yeast/) contain an enormous amount of information 
concerning S. cerevisiae genes, open reading frames, and gene products. The yeast S. 
cerevisiae became a well established eukaryotic model organism to study fundamental 
biological processes such as aging, mRNA transport, the cell cycle, and many more. 
Saccharomyces cerevisiae grows well in a simple chemically defined medium, under acidic 
conditions, even at pH values equal 3. At such low pH values, many weak acids, including 
succinate, occur predominantly in their undissociated form. This is advantageous for 
industrial production, as it reduces the need for titration with alkali and allows for direct 
recovery of undissociated acids. Consequently, there is no need for large quantities of 
acidifying agents, and the formation of salt byproducts (e.g. gypsum) is strongly reduced.  
In addition, S. cerevisiae robust tolerance in acidic conditions represents a major advantage 
in that it lowers the risk of contamination in industrial fermentation [44, 49].  
The yeast-based fermentation process, which operates at a much lower pH than competing 
processes, allows succinic acid to be produced with a significantly higher energy efficiency 
compared to the traditional method. This compound is not accumulated intracellularly. It is 
also one of the first bio-based processes that sequesters carbon dioxide in the production 
process [47, 53]. This makes the yeast Saccharomyces cerevisiae a suitable and promising 
candidate for the biotechnological production of succinic acid on an industrial scale. 
The metabolic engineering strategy was used for the oxidative production of succinic acid 
by deletion SDH1, SDH2 genes in the genome. Arikawa et al. [55] reported an increased 
succinic acid productivity in sake yeast strains with deletions of TCA cycle genes. In 
comparison to the wild-type, succinate levels were increased up to2.7 fold in a strain with 
simultaneous disruption of a subunit of succinate dehydrogenase (SDH1) and fumarase 
(FUM1) under aerobic conditions. The single deletion of gene SDH1 led to a1.6-fold increase 
of succinic acid production. In another study on sake yeast strains, the deletion of genes 
encoding for succinate dehydrogenase subunits (SDH1, SDH2, SDH3, and SDH4) also 
resulted inincreased succinate productivity in aerobic conditions. Raab et al. [48] reported 
the construction of yeast strains for the biotechnological production of succinic acid. The 
genes SDH1, SDH2, IDH1 and IDP1, which encode mitochondrial enzymes were deleted 
with the aim to disrupt succinate and isocitrate dehydrogenase activity to redirect the 
carbon flux and to allow succinate to accumulate as an end-product. This study showed that 
the yeast S. cerevisiae is capable of synthesizing significant amounts of succinic acid, which is 
exported quantitatively into the culture broth and not being accumulated intracellularly. 
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The constructed yeast strains with disruptions in the TCA cycle produced succinic acid up 
to 3.62 g/L at a yield of 0.11 mol /mol glucose in shake flask cultures.  
Saccharomyces cerevisiae is one of the most highly researched model organisms in different 
biological studies. Using this yeast we can effectively re-examine long-standing and 
fundamental questions regarding regulation of metabolism and prediction of dynamic 
models in various cells, including mammalian tissues. This is a considerable knowledge 
about the composition, enzymology and membrane binding of the enzyme and relatively 
new discoveries about its genetics and biosynthesis. Through such efforts, we are able to 
identify key features of cellular metabolic pathways which can be use both in medicine and 
in different biotechnological processes. 
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